Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives

Black Diamond Therapeutics (BDTX) just posted a sharp swing into profit for FY 2025, with first half revenue of US$70 million translating to basic EPS of US$0.81, compared with losses in both halves of FY 2024. Over the past year, the company has seen revenue move from US$0 to US$70 million while basic EPS has shifted from losses of US$0.71 and US$0.56 in FY 2024 to a trailing 12 month figure of US$0.25. This sets up a results season where investors will focus squarely on how durable these margins look after such a turnaround.

See our full analysis for Black Diamond Therapeutics.

With the headline numbers on the table, the next step is to set these results against the prevailing market narratives to see which views hold up and which start to look out of date.

Curious how numbers become stories that shape markets? Explore Community Narratives

US$14.4 million profit over the last 12 months

• On a trailing 12 month basis, Black Diamond reports net income of US$14.4 million and basic EPS of US$0.25, compared with a net loss of US$69.7 million and basic EPS of US$1.27 loss in the prior 12 month period captured in the data.
• What stands out for bullish investors is that this move into profit lines up with five year annualized earnings growth of 26.1%, yet forecasts still call for earnings to decline about 13.6% per year over the next three years. This creates a clear tension between the recent profitability shift and the more cautious outlook.
  • The step from a US$69.7 million loss to a US$14.4 million profit, alongside revenue moving from US$0 to US$70 million over the same trailing window, strongly supports the bullish view that the business model can generate earnings at scale.
  • At the same time, the projected 13.6% annual earnings decline means the bullish case has to explain why current positive figures may not be sustained in the way recent history might suggest.

Forecast 76.7% revenue growth versus earnings decline

• Forward looking estimates point to revenue growth of about 76.7% per year, while earnings are forecast to fall roughly 13.6% per year over the next three years, so top line and bottom line are expected to move in opposite directions.
• Bears focus on this split, arguing that projected earnings declines outweigh strong revenue growth, and the data here gives them specific figures to point to while also leaving room for debate about how this plays out.
  • The shift to US$14.4 million of trailing net income and basic EPS of US$0.25 shows earnings are currently positive, which challenges a purely bearish view that the business cannot produce profit even as it scales.
  • However, the explicit forecast for a 13.6% annual drop in earnings, despite the 76.7% revenue growth outlook, supports the cautious argument that future profitability may not track revenue one for one.

P/E of 5.9x versus 18.4x US market

• Black Diamond trades on a trailing P/E of 5.9x, compared with a US market average of 18.4x, a peer average of 16.9x, and a US biotechs industry average of 20.6x.
• For both bullish and bearish investors, the key question is how this low multiple fits alongside the shift to profitability and strong revenue forecasts on one hand, and projected earnings declines on the other.
  • The move to US$14.4 million of trailing net income and positive EPS helps explain why the stock can be valued on earnings at all, and gives bulls a concrete reason to say the 5.9x P/E looks low relative to the business now earning money.
  • Yet with consensus expecting earnings to fall about 13.6% per year even as revenue is forecast to grow 76.7% per year, bears can argue the discount versus the 18.4x market and 20.6x biotech averages reflects those risks rather than a simple mispricing.

For a broader read on how others are connecting these numbers to the longer term story, it is worth seeing how the community is framing the balance of growth, profitability, and risks in one place, and the easiest way to do that is to tap into the range of shared views that sit alongside this kind of data driven summary. 📊 Read the what the Community is saying about Black Diamond Therapeutics.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Black Diamond Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of strong revenue forecasts, current profit and cautious earnings projections feels mixed, that is exactly why it pays to look at the details yourself and not rely on any single narrative. To round out your own view before making a decision, check the 4 key rewards and 1 important warning sign

See What Else Is Out There

Despite the recent swing into profit, the forecasts for a 13.6% annual earnings decline alongside strong revenue growth highlight concerns about how resilient those profits may be.

If you want ideas where the earnings picture and balance sheet may look more robust, check out the solid balance sheet and fundamentals stocks screener (42 results) to quickly spot companies built for durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com